lobular carcinoma in-situ (LCIS)
Jump to navigation
Jump to search
Introduction
breast lobular carcinoma in situ.
Pathology
- abnormal cells within the lobules of the breast
- considered a marker for increased risk of cancer, not itself an invasive cancer
Laboratory
- LCIS in breast cancer specimen
- nearly always estrogen receptor positive Complication:
- increased risk for development of
- invasive breast ductal carcinoma
- invasive breast lobular carcinoma
Management
- tamoxifen for premenopausal women
- tamoxifen or aromatase inhibitor for post-menopausal women
- radiation therapy not indicated
- bilateral mastectomy &/or bilateral salpingo-oophorectomy for patients with BRCA1 mutation or BRCA2 mutation
More general terms
References
- ↑ Afonso N, Bouwman D. Lobular carcinoma in situ. Eur J Cancer Prev. 2008 Aug;17(4):312-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18562954 Review.